m201-a
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 17, 2017 (NCT03055403)
Timeline
Indications
Mechanism of action
- Ryanodine receptor 1MODULATOR
RYR1 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- m201-a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04464681 | Phase 1 | Mar 30, 2020 | Aetas Pharma Co., Ltd., Kitasato University |
| NCT04609059 | Phase 2 | May 7, 2019 | Aetas Pharma Co., Ltd., Kitasato University |
| NCT03055403 | Phase 1 | Feb 17, 2017 | Aetas Pharma Co., Ltd., Kitasato University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aetas Pharma Co., Ltd. | For profit | 3 | 0 | 2 | 2017 |
| Kitasato University | Academic/Hospital | 3 | 3 | 2 | 2017 |
2 organizations
Page 1 / 1